Eisai Inc. recently announced that Fycompa (perampanel) Oral Suspension is now available for patients who have epilepsy, a condition that can make it challenging to swallow tablets.
The medical condition epilepsy causes seizures that can affect several different physical and mental functions among patients. There are currently 2.9 million epileptic patients in the U.S.
The U.S. Food and Drug Administration (FDA) approved the new treatment as an adjunctive therapy to treat partial-onset seizures as well as primary generalized tonic-clonic seizures.
Fycompa Oral Suspension is a novel bioequivalent interchangeable alternative. With this treatment, patients don’t need to swallow tablets. Qualifying patients must be at least 12 years old.
Eisai provides patients who have Fycompa Savings Cards with commercial insurance. This means that qualifying patients only need to pay $10 for monthly prescriptions of Fycompa.
"Swallowing tablets can be a real concern for some patients with epilepsy," Lynn Kramer, chief medical officer of Neurology Business Group, Eisai, said. "We are proud to offer this new option, which reinforces Eisai's ongoing commitment to advancing epilepsy care and addressing the unmet medical needs of patients and their families."
To activate a savings card, go to at Fycompa.com. This card can be received through a doctor, a download or a printed copy at home. Counselor assistance is available for patients.
